US7214696 — Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Method of Use · Assigned to Scripps Research Institute · Expires 2026-12-19 · 1y remaining
What this patent protects
This patent protects methods and compounds for stabilizing the protein transthyretin and preventing its misfolding.
USPTO Abstract
Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods, screening methods, as well as specific transthyretin stabilizing compounds are disclosed.
Drugs covered by this patent
- Vyndaqel (Tafamidis Meglumine) · Foldrx Pharms
- Vyndaqel (tafamidis) · Foldrx Pharms
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2524 |
— | Vyndaqel |
U-2524 |
— | Vyndaqel |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.